Medpace Holdings stock overview

Medpace Holdings (MEDP) has recently drawn investor attention after a period of weaker share performance, with the stock showing declines over the past week, month and past 3 months alongside a lower year to date return.

At a share price of US$423.93, Medpace’s recent pullback, including a 30 day share price return of a 29.25% decline, contrasts with its 1 year total shareholder return of 25.99%. This hints at fading short term momentum while longer term holders remain ahead.

If this volatility has you looking beyond a single stock, it could be a good moment to scan other healthcare related opportunities using our screener of 25 healthcare AI stocks.

With Medpace showing a sharp recent pullback yet still delivering a 1 year total return of 25.99% and trading below some estimated value measures, you have to ask: is this a genuine entry point, or is future growth already priced in?

Most Popular Narrative: 22.3% Undervalued

At $423.93 a share versus a narrative fair value of $545.75, Medpace is framed as materially undervalued, with that gap hinging on specific long term assumptions.

The updated analyst framework edges fair value for Medpace Holdings slightly higher to about $545.75 from roughly $541.92. This reflects modest tweaks to discount rate, growth, margin and P/E assumptions as analysts respond to a series of recent price target increases across the Street.

Curious what kind of revenue pace, profit margins and future P/E multiple are baked into that fair value? The full narrative lays out a precise earnings and valuation roadmap.

Result: Fair Value of $545.75 (UNDERVALUED)

However, you still need to weigh risks such as a declining backlog and higher hiring and operating costs, which could pressure future revenue visibility and margins.

Build Your Own Medpace Holdings Narrative

If you are not fully aligned with this view or simply prefer to weigh the numbers yourself, you can still shape a custom thesis in just a few minutes, starting with Do it your way.

A great starting point for your Medpace Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Medpace has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused ideas that could round out your portfolio research.

• Start widening your opportunity set with screener containing 24 high quality undiscovered gems that many investors are not paying attention to yet.
• Prioritise resilience by checking out 85 resilient stocks with low risk scores that score well on our risk filters.
• Strengthen your focus on financial robustness with our solid balance sheet and fundamentals stocks screener (45 results) that stand out for cleaner balance sheets and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.